Raymond is Head of Autism Genetics at the Ingham Institute for Applied Medical Research. He was awarded his PhD while working with early transgenic technologies to express genes in mice. Raymond was awarded a Postdoctoral Position of Excellence with the Commonwealth Scientific & Industrial Research Organisation of Australia in the study of Immunogenetics of Animal Health and Welfare and from where moved to the St George Clinical School of Medicine with the University of NSW. Dr Clarke was first to discover the gene (GDF6) causing a progressive familial form of spinal fusions in a variant form of Klippel-Feil syndrome known as multiple synostosis syndrome type 4. Raymond was also a member of the research group that identified the first breast cancer-associated gain-of-function mutations in the ATM gene, which established ATM's role as a breast cancer tumour suppressor gene. Next, Raymond discovered the TOSPEAK gene that regulates the evolutionary development of the capacity to speak through transcriptional interference. Then with the University of Western Sydney Raymond described the first fully intersecting pathogenetic model for Tourette syndrome (GTS) that implicated all of the neurexins and all of their known trans-synaptic ligands in GTS and autism. Raymond is now developing molecular medicines for autism.